These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 9876826)

  • 1. Comment: mibefradil, a new class of calcium-channel antagonists.
    Otterman S
    Ann Pharmacother; 1998 Dec; 32(12):1372. PubMed ID: 9876826
    [No Abstract]   [Full Text] [Related]  

  • 2. The withdrawal of mibefradil (Posicor).
    Griffin JP
    Adverse Drug React Toxicol Rev; 1998; 17(2-3):59-60. PubMed ID: 9838964
    [No Abstract]   [Full Text] [Related]  

  • 3. Mibefradil--a new calcium-channel blocker.
    Med Lett Drugs Ther; 1997 Nov; 39(1013):103-5. PubMed ID: 9391500
    [No Abstract]   [Full Text] [Related]  

  • 4. What lessons can be learnt from withdrawal of mibefradil from the market?
    Po AL; Zhang WY
    Lancet; 1998 Jun; 351(9119):1829-30. PubMed ID: 9652662
    [No Abstract]   [Full Text] [Related]  

  • 5. Mibefradil withdrawn from the market.
    Billups SJ; Carter BL
    Ann Pharmacother; 1998; 32(7-8):841. PubMed ID: 9681103
    [No Abstract]   [Full Text] [Related]  

  • 6. Rhabdomyolysis due to interaction of simvastatin with mibefradil.
    Schmassmann-Suhijar D; Bullingham R; Gasser R; Schmutz J; Haefeli WE
    Lancet; 1998 Jun; 351(9120):1929-30. PubMed ID: 9654265
    [No Abstract]   [Full Text] [Related]  

  • 7. Mibefradil and an effective formulary system.
    Vermeulen LC; Dunham DB
    Am J Health Syst Pharm; 1998 Sep; 55(18):1934-5. PubMed ID: 9784776
    [No Abstract]   [Full Text] [Related]  

  • 8. [Induction of bradycardia by mibefradil in antihypertensive combination therapy].
    Wagner J; Ritz E
    Dtsch Med Wochenschr; 1998 Apr; 123(17):547. PubMed ID: 9601479
    [No Abstract]   [Full Text] [Related]  

  • 9. Profound symptomatic bradycardia associated with combined mibefradil and beta-blocker therapy.
    Rogers R; Prpic R
    Med J Aust; 1998 Oct; 169(8):425-7. PubMed ID: 9830391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The short life and rapid death of a novel antihypertensive and antianginal agent.
    Krum H; McNeil JJ
    Med J Aust; 1998 Oct; 169(8):408-9. PubMed ID: 9830386
    [No Abstract]   [Full Text] [Related]  

  • 11. Mibefradil (Posicor) induced sinus arrest.
    Sanders P; Walker J; Craig RJ; Hii JT; Steele PM
    Aust N Z J Med; 1998 Dec; 28(6):836-7. PubMed ID: 9972419
    [No Abstract]   [Full Text] [Related]  

  • 12. Withdrawal of Posicor from market.
    SoRelle R
    Circulation; 1998 Sep; 98(9):831-2. PubMed ID: 9738634
    [No Abstract]   [Full Text] [Related]  

  • 13. Serious interaction between mibefradil and tacrolimus.
    Krähenbühl S; Menafoglio A; Giostra E; Gallino A
    Transplantation; 1998 Oct; 66(8):1113-5. PubMed ID: 9808502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From the Food and Drug Administration.
    Nightingale SL
    JAMA; 1998 Feb; 279(5):346. PubMed ID: 9459455
    [No Abstract]   [Full Text] [Related]  

  • 15. Mibefradil (posicor).
    Giles TD
    Compr Ther; 1997 Nov; 23(11):761-3. PubMed ID: 9360806
    [No Abstract]   [Full Text] [Related]  

  • 16. Mibefradil: a new class of calcium-channel antagonists.
    Billups SJ; Carter BL
    Ann Pharmacother; 1998 Jun; 32(6):659-71. PubMed ID: 9640486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case report: rhabdomyolysis induced by mibefradil in a patient treated with cyclosporine and simvastatin.
    Wombolt DG; Jackson A; Punn R; Smith S; McCune TR; Williams PB
    J Clin Pharmacol; 1999 Mar; 39(3):310-2. PubMed ID: 10073331
    [No Abstract]   [Full Text] [Related]  

  • 18. Good news for experimental concept but bad news for clinically effective therapy.
    Reimer KA; Califf RM
    Circulation; 1999 Jan; 99(2):198-200. PubMed ID: 9892582
    [No Abstract]   [Full Text] [Related]  

  • 19. Mibefradil, a pharmacologically distinct calcium antagonist.
    Ernst ME; Kelly MW
    Pharmacotherapy; 1998; 18(3):463-85. PubMed ID: 9620098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of calcium channel blockers and beta blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. The Netherlands Working Group on Cardiovascular Research (WCN).
    van der Vring JA; Daniëls MC; Holwerda NJ; Withagen PJ; Schelling A; Cleophas TJ; Hendriks MG
    Angiology; 1999 Jun; 50(6):447-54. PubMed ID: 10378820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.